Nektar Therapeutics stock faces a trial data checkpoint

Nektar Therapeutics stock carried a USD 1.7 billion market capitalization as of September 30, 2026, while its Nasdaq close was USD 60.55. The company is presenting six-month off-treatment data for rezpegaldesleukin at the EADV Congress, giving the pipeline its next clinical checkpoint.

Trial data sets the next checkpoint

According to Nektar Therapeutics in its September 28, 2026 release, the company scheduled three oral presentations on rezpegaldesleukin at the European Academy of Dermatology and Venereology Congress. The key update is six-month off-treatment follow-up from the 92-patient Phase 2b REZOLVE-AA study in severe-to-very-severe alopecia areata.

The same release described additional REZOLVE-AD maintenance data in atopic dermatitis and a late-breaking multi-omic biomarker presentation. The presentations connect the investment case to durability after treatment and to biological signals that could support later development decisions.

Analyst targets remain widely split

Price targets show how sharply expectations differ. Markets Insider reported on September 28, 2026, that Canaccord Genuity maintained a Buy rating and a USD 153.00 price target. By contrast, MarketBeat reported on September 23, 2026, that Wedbush cut its target from USD 80.00 to USD 50.00 and retained a Neutral rating.

The spread matters because Nektar remains a clinical-stage biotechnology company. The upcoming evidence must therefore add measurable confidence to rezpegaldesleukin development rather than simply extend an existing research narrative.

Revenue remains tied to royalties

For the quarter ended June 30, 2026, Nektar reported USD 10.13 million of revenue and a USD 40.62 million GAAP net loss, compared with USD 11.18 million of revenue and a USD 41.59 million GAAP net loss a year earlier, according to Markets Insider. Revenue declined year over year, while the reported net loss narrowed by USD 0.97 million.

Nektar closed at USD 60.55 on Nasdaq on September 30, 2026, at 4:00 p.m. EDT. Its 52-week range was USD 33.40 to USD 109.00, placing the close USD 48.45 below the yearly high and leaving clinical execution as the central valuation variable.